GILEAD SCIENCES, INC. for GILEAD SCIENCES INC

Trade (domestic/foreign) TRD

International trade and protection of intellectual property; TRIPS Waiver; compulsory licensing and other IP issues in multiple countries.

Contacted: Health & Human Services, Dept of (HHS); Patent & Trademark Office (PTO); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Food & Drug Administration (FDA); Commerce, Dept of (DOC); Office of the Vice President of the United States; White House Office; SENATE; State, Dept of (DOS); U.S. Trade Representative (USTR); Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS)

Taxation/Internal Revenue Code TAX

Proposals to change corporate tax rates and related laws as part of budget reconciliation process

Contacted: Office of the Vice President of the United States; Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA); Natl Institutes of Health (NIH); Centers For Medicare and Medicaid Services (CMS); SENATE; Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); White House Office; U.S. Trade Representative (USTR); State, Dept of (DOS); Commerce, Dept of (DOC)

Copyright/Patent/Trademark CPT

Issues related to pharmaceuticals and intellectual property protection including technology transfer, patent rights and funding.

Contacted: Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); White House Office; SENATE; Office of Management & Budget (OMB); Food & Drug Administration (FDA); State, Dept of (DOS); Natl Institutes of Health (NIH); Centers For Medicare and Medicaid Services (CMS); Office of the Vice President of the United States

Health Issues HCR

Advocate on drug pricing proposals, including reconciliation legislation, and expanding access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Engage on pharmaceutical policy as it relates to payments under the 340B program. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments for COVID-19 (2019 Novel Coronavirus), including: manufacturing, clinical trials, reimbursement and coverage of Veklury (remdesivir).

Contacted: Patent & Trademark Office (PTO); Office of the Vice President of the United States; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Commerce, Dept of (DOC); SENATE; Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); Office of Management & Budget (OMB); White House Office; Natl Institutes of Health (NIH); State, Dept of (DOS); U.S. Trade Representative (USTR)

Medicare/Medicaid MMM

Advocate on drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements.

Contacted: State, Dept of (DOS); SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); Centers For Disease Control & Prevention (CDC); White House Office; Natl Institutes of Health (NIH); Centers For Medicare and Medicaid Services (CMS); Office of the Vice President of the United States; Commerce, Dept of (DOC); Patent & Trademark Office (PTO)

Budget/Appropriations BUD

Funding for Hepatitis C, HIV, and public health activities via appropriations. Drug pricing proposals and budget reconciliation. S.Con.Res.14.

Contacted: White House Office; State, Dept of (DOS); SENATE; HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO); Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Natl Institutes of Health (NIH); Centers For Disease Control & Prevention (CDC); U.S. Trade Representative (USTR); Office of the Vice President of the United States; Commerce, Dept of (DOC); Centers For Medicare and Medicaid Services (CMS)

Bills named: S.Con.Res. 14 (117th)